A Phase 1 interventional study of Gepotidacin and Placebo in Infections, Bacterial, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 12 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-04.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing gepotidacin in Bacterial Infections — 1 open to participants now, 1 under way, none of them phase 3. gepotidacin · Bacterial Infections.
Among the 11 studies testing gepotidacin in Bacterial Infections, this one is the 6th largest by enrollment, is the only one that started in 2019, is one of 9 in phase 1, and was the 8th registered.
584 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →1 of the 11 studies testing gepotidacin in Bacterial Infections is open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 2–11
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.
This study: 12 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2019.
This study's enrollment of 34 is below the median of 84 across 382 interventional studies indexed under Bacterial Infections.
Median enrollment 34 across the 11 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 2 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Bacterial Infections by GlaxoSmithKline: 1 open now, 1 under way, none of them phase 3. Of 29 finished, 13 (45%) have results posted.
Among the 35 studies in Bacterial Infections by GlaxoSmithKline, this one is the 15th largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2019, is one of 28 in phase 1, and was the 32nd registered.
GlaxoSmithKline’s Bacterial Infections studies by the year they started, since 2005.
1 of the studies testing gepotidacin in Bacterial Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07371429GlaxoSmithKlineA Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics | 2027-08-23 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing gepotidacin in Bacterial Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Bacterial Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is double-blind, randomized, sequential, two part study. Part 1 is a 3 periods, fixed-sequence study and will be conducted to evaluate the pharmacokinetics, safety, and tolerability of the gepotidacin tablet in healthy adult subjects. Part 2 is a 2 periods, fixed-sequence study and will evaluate the pharmacokinetics, safety, and tolerability of the gepotidacin tablet in healthy adolescent subjects. The primary purpose of Part 1 is to evaluate the pharmacokinetics of a single 1500 milligram (mg) dose and two 3000 mg doses of gepotidacin given 6 and 12 hours apart in adult subjects; Part 2 is to evaluate the pharmacokinetics of a single 1500 mg dose and two 3000 mg doses of gepotidacin given at a dosing interval (to be determined based on the pharmacokinetic and safety results from Part 1) in adolescent subjects. The duration of Part A will be approximately 47 days and 52 days for Part 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy adult subjects will receive a single oral dose of gepotidacin 1500 mg (2 X 750 mg, treatment A), tablets, on Day 1 of Period 1; two oral doses of gepotidacin 3000 mg (4 x 750 mg, Treatment C), tablets, at 0 and 12 hours on Day 5 of Period 2; and two oral doses of gepotidacin 3000 mg (4 x 750 mg, treatment E), tablets, at 0 and 6 hours on Day 9 of Period 3.
Drug: Gepotidacin
Healthy adult subjects will receive a single oral dose of matching placebo (treatment B), tablets, on Day 1 of Period 1; two oral doses of matching placebo (treatment D), tablets, at 0 and 12 hours on Day 5 of Period 2; and two oral doses of matching placebo (treatment F), tablets, at 0 and 6 hours on Day 9 of Period 3.
Drug: Placebo
Healthy adolescent subjects will receive a single oral dose of gepotidacin 1500 mg (2 x 750 mg, treatment A), tablets, on Day 1 of Period 1; and two oral doses of gepotidacin 3000 mg (4 x 750 mg, treatment G), tablets, at 0 and 6 hours on Day 1 of Period 2.
Drug: Gepotidacin
Healthy adolescent subjects will receive a single oral dose of matching placebo (treatment B), tablets on Day 1 of Period 1; and two oral doses of matching placebo (treatment H), tablets at 0 and 6 hours on Day 1 of Period 2.
Drug: Placebo
Tablets containing gepotidacin mesylate with a unit dose of 750 mg will be administered orally with 240 milliliter (mL) of water.
Tablets containing unit dose of placebo matching of gepotidacin will be administered orally with 240 mL of water.
Part 1- Period 1: Area Under the Concentration-time Curve From Time 0 (Pre-dose) to Time of the Last Quantifiable Concentration (AUC[0-t]) After Single Dose Administration of Gepotidacin 1500 mg
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Part 1- Period 1: Area Under the Concentration-time Curve From Time 0 (Pre-dose) Extrapolated to Infinite Time (AUC[0-infinity]) After Single Dose Administration of Gepotidacin 1500 mg
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Part 1- Period 1: Area Under the Concentration-time Curve From Time 0 (Pre-dose) to 24 Hours Post-dose (AUC[0-24]) After Single Dose Administration of Gepotidacin 1500 mg
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours post-dose
Part 1- Period 1: Area Under the Concentration-time Curve From Time 0 (Pre-dose) to 48 Hours Post-dose (AUC[0-48]) After Single Dose Administration of Gepotidacin 1500 mg
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Part 1- Period 1: Maximum Observed Concentration (Cmax) After Single Dose Administration of Gepotidacin 1500 mg
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Part 1- Period 2: AUC(0-t) Following Two Doses of Gepotidacin 3000 mg Administered at 12 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, 24, 36, 48 and 60 hours post-dose
Part 1- Period 3: AUC(0-t) Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18, 24, 36, 48 and 60 hours post-dose
Part 1- Period 2: Area Under the Concentration-time Curve From Time 0 (Pre-dose) to Time Tau (Tau=12) (AUC[0-tau]) Following Two Doses of Gepotidacin 3000 mg Administered at 12 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 hours post-dose
Part 1- Period 3: AUC(0-tau) (Tau=6) Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin.PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4 and 6 hours post-dose
Part 1- Period 2: AUC(0-24) Following Two Doses of Gepotidacin 3000 mg Administered at 12 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20 and 24 hours post-dose
Part 1- Period 3: AUC(0-24) Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18 and 24 hours post-dose
Part 1- Period 2: AUC(0-48) Following Two Doses of Gepotidacin 3000 mg Administered at 12 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, 24, 36 and 48 hours post-dose
Part 1- Period 3: AUC(0-48) Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18, 24, 36 and 48 hours post-dose
Part 1- Period 2: Accumulation Ratio for Cmax (RoCmax) Following Two Doses of Gepotidacin 3000 mg Administered at 12 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio was calculated as Cmax after the second dose divided by Cmax after the first dose.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, 24, 36, 48 and 60 hours post-dose
Part 1- Period 2: Accumulation Ratio for AUC (RoAUC) Following Two Doses of Gepotidacin 3000 mg Administered at 12 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio was calculated as AUC(0-tau) after the second dose, where 0 is the timepoint prior to second dose, divided by AUC(0-tau) after the first dose, where 0 is the predose timepoint prior to the first dose.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, 24, 36, 48 and 60 hours post-dose
Part 1- Period 3: RoCmax Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio was calculated as Cmax after the second dose divided by Cmax after the first dose.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18, 24, 36, 48 and 60 hours post-dose
Part 1- Period 3: RoAUC Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio was calculated as AUC(0-tau) after the second dose, where 0 is the timepoint prior to second dose, divided by AUC(0-tau) after the first dose, where 0 is the predose timepoint prior to the first dose.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18, 24, 36, 48 and 60 hours post-dose
Part 1- Period 2: Cmax Following Two Doses of Gepotidacin 3000 mg Administered at 12 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, 24, 36, 48 and 60 hours post-dose
Part 1- Period 3: Cmax Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18, 24, 36, 48 and 60 hours post-dose
Part 2- Period 1: AUC(0-t) After Single Dose Administration of Gepotidacin 1500 mg
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Part 2- Period 1: AUC(0-infinity) After Single Dose Administration of Gepotidacin 1500 mg
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Part 2- Period 1: AUC(0-24) After Single Dose Administration of Gepotidacin 1500 mg
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours post-dose
Part 2- Period 1: AUC(0-48) After Single Dose Administration of Gepotidacin 1500 mg
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Part 2- Period 1: Cmax After Single Dose Administration of Gepotidacin 1500 mg
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Part 2- Period 2: AUC(0-t) Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18, 24, 36 and 48 hours post-dose
Part 2- Period 2: AUC(0-tau) (Tau=6) Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4 and 6 hours post-dose
Part 2- Period 2: AUC(0-24) Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18 and 24 hours post-dose
Part 2- Period 2: AUC(0-48) Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18, 24, 36 and 48 hours post-dose
Part 2- Period 2: Cmax Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18, 24, 36 and 48 hours post-dose
Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Number of participants with common (\>=5%) non-serious AEs and SAEs is presented.
Time frame: Up to Day 19
Part 2: Number of Participants With Non-serious AEs and SAEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Number of participants with common (\>=5%) non-serious AEs and SAEs are presented.
Time frame: Up to Day 21
Part 1: Number of Participants With Hematology Toxicities of Grade 3 or Higher
Blood samples were collected for the analysis of following hematology parameters: platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), white blood cell (WBC) count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. The hematology abnormalities were graded using the Division of Microbiology and Infectious Diseases toxicity grading where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe and Grade 4=Life-threatening. Number of participants with a grade 3 or higher toxicity for any of the hematology parameter is presented.
Time frame: Up to Day 19
Part 2: Number of Participants With Hematology Toxicities of Grade 3 or Higher
Blood samples were collected for the analysis of following hematology parameters: platelet count, RBC count, hemoglobin, hematocrit, MCV, MCH, WBC count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. The hematology abnormalities were graded using the Division of Microbiology and Infectious Diseases toxicity grading where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe and Grade 4=Life-threatening. Number of participants with a grade 3 or higher toxicity for any of the hematology parameter is presented.
Time frame: Up to Day 21
Part 1: Number of Participants With Clinical Chemistry Toxicities of Grade 3 or Higher
Blood samples were collected for the analysis of following clinical chemistry parameters: blood urea nitrogen (BUN), creatinine, glucose (fasting), potassium, sodium, magnesium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, total and direct bilirubin, creatine phosphokinase, calcium, chloride, carbon dioxide, total protein and albumin. The clinical chemistry abnormalities were graded using the Division of Microbiology and Infectious Diseases toxicity grading where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe and Grade 4=Life-threatening. Number of participants with a grade 3 or higher toxicity for any of the clinical chemistry parameter is presented
Time frame: Up to Day 19
Part 2: Number of Participants With Clinical Chemistry Toxicities of Grade 3 or Higher
Blood samples were collected for the analysis of following clinical chemistry parameters: BUN, creatinine, glucose (fasting), potassium, sodium, magnesium, AST, ALT, alkaline phosphatase, total and direct bilirubin, creatine phosphokinase, calcium, chloride, carbon dioxide, total protein and albumin. The clinical chemistry abnormalities were graded using the Division of Microbiology and Infectious Diseases toxicity grading where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe and Grade 4=Life-threatening. Number of participants with a grade 3 or higher toxicity for any of the clinical chemistry parameter is presented
Time frame: Up to Day 21
Part 1: Number of Participants With Urinalysis Toxicities of Grade 3 or Higher
Urine samples were collected for the analysis of urine parameters including specific gravity, potential of hydrogen (pH), glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase. Toxicities were graded using the Division of Microbiology and Infectious Diseases toxicity grading where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe and Grade 4=Life-threatening. Number of participants with a grade 3 or higher toxicity for any of the urine parameter is presented
Time frame: Up to Day 19
Part 2: Number of Participants With Urinalysis Toxicities of Grade 3 or Higher
Urine samples were collected for the analysis of urine parameters including specific gravity, pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase. Toxicities were graded using the Division of Microbiology and Infectious Diseases toxicity grading where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe and Grade 4=Life-threatening. Number of participants with a grade 3 or higher toxicity for any of the urine parameter is presented
Time frame: Up to Day 21
Part 1: Number of Participants With Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) of Potential Clinical Importance
SBP and DBP were measured in a semi-supine position after 5 minutes of rest. The potential clinically important range for vital signs were: SBP (lower: \<85 and upper: \>160 millimeters of mercury \[mmHg\]) and DBP (lower: \<45 and upper: \>100 mmHg).
Time frame: Up to Day 19
Part 2: Number of Participants With SBP and DBP of Potential Clinical Importance
SBP and DBP were measured in a semi-supine position after 5 minutes of rest. The potential clinically important range for vital signs were: SBP (lower: \<85 and upper: \>160 mmHg) and DBP (lower: \<45 and upper: \>100 mmHg).
Time frame: Up to Day 21
Part 1: Number of Participants With Abnormal Heart Rate of Potential Clinical Importance
Heart rate was measured in a semi-supine position after 5 minutes of rest. The potential clinically important range for heart rate was (lower:\<40 and upper: \>110 beats per minute).
Time frame: Up to Day 19
Part 2: Number of Participants With Abnormal Heart Rate of Potential Clinical Importance
Heart rate was measured in a semi-supine position after 5 minutes of rest. The potential clinically important range for heart rate was (lower:\<40 and upper: \>110 beats per minute).
Time frame: Up to Day 21
Part 1: Period 1: Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and corrected QT (QTc) intervals and calculated heart rate. Data for abnormal not clinically significant (NCS) and clinically significant (CS) ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
Time frame: Predose, predose 2, predose 3, 0.5. 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours on Day 1, 24, 36 hours on Day 2 and 48 hours on Day 3.
Part 1: Period 2: Number of Participants With Abnormal 12-lead ECG Findings
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and QTc intervals and calculated heart rate. Data for abnormal NCS and CS ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
Time frame: Predose, predose 2, predose 3, 0.5. 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20 hours on Day 1, 24, 36 hours on Day 2, 48 and 60 hours on Day 3
Part 1: Period 3: Number of Participants With Abnormal 12-lead ECG Findings
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and QTc intervals and calculated heart rate. Data for abnormal NCS and CS ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
Time frame: Predose, predose 2, predose 3, 0.5. 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18 hours on Day 1, 24, 36 hours on Day 2, 48 and 60 hours on Day 3
Part 2: Period 1: Number of Participants With Abnormal 12-lead ECG Findings
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and QTc intervals and calculated heart rate. Data for abnormal NCS and CS were presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
Time frame: Predose, predose 2, predose 3, 0.5. 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours on Day 1, 24, 36 hours on Day 2 and 48 hours on Day 3
Part 2: Period 2: Number of Participants With Abnormal 12-lead ECG Findings
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and QTc intervals and calculated heart rate. Data for abnormal NCS and CS were presented CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
Time frame: Predose, predose 2, predose 3, 0.5. 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18 hours on Day 1, 24, 36 hours on Day 2 and 48 hours on Day 3
Part 1- Period 1: Total Unchanged Drug (Ae Total) After Single Dose Administration of Gepotidacin 1500 mg
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. Ae total was calculated by adding all the fractions of drug collected over all the allotted time intervals.
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-36 and 36-48 hours post-dose
Part 1- Period 1: Amount of Drug Excreted in Urine in a Time Interval (Ae[t1-t2]) After Single Dose Administration of Gepotidacin 1500 mg
Urine samples were collected at the specified intervals for PK analysis. PK parameters were calculated using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
Time frame: 0-2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-36 and 36-48 hours post-dose
Part 1- Period 1: AUC(0-24) After Single Dose Administration of Gepotidacin 1500 mg (Urine)
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin.
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-12 and 12-24 hours post-dose.
Part 1- Period 1: AUC(0-48) After Single Dose Administration of Gepotidacin 1500 mg (Urine)
Urine samples were be collected at indicated time points for pharmacokinetic analysis of gepotidacin.
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-36 and 36-48 hours post-dose
Part 1- Period 1: Percentage of the Given Dose of Drug Excreted in Urine (fe%) After Single Dose Administration of Gepotidacin 1500 mg
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. fe% was calculated as: (Ae total/Dose) x 100 percent (%).
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-36 and 36-48 hours post-dose
Part 1- Period 1: Renal Clearance of Drug (CLr) After Single Dose Administration of Gepotidacin 1500 mg
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t)
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-36 and 36-48 hours post-dose
Part 1- Period 2: Ae Total After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval
Urine samples were collected at indicated time points. Ae total were calculated by adding all the fractions of drug collected over all the allotted time intervals.
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-12, 12-14, 14-16, 16-18, 18-20, 20-24, 24-36, 36-48 and 48-60 hours post-dose
Part 1- Period 3: Ae Total After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval
Urine samples were collected at indicated time points. Ae total were calculated by adding all the fractions of drug collected over all the allotted time intervals
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-18, 18-24, 24-36, 36-48 and 48-60 hours post-dose
Part 1- Period 2: Ae(t1-t2) After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals
Time frame: 0-2, 2-4, 4-6, 6-8, 8-12, 12-14, 14-16, 16-18, 18-20, 20-24, 24-36, 36-48 and 48-60 hours post-dose
Part 1- Period 3: Ae(t1-t2) After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
Time frame: 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-18, 18 -24, 24-36, 36-48 and 48-60 hours post-dose
Part 1- Period 2: AUC(0-tau) (Tau=12 Hours Post-dose) After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval (Urine)
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin.
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8 and 8-12 hours post-dose
Part 1- Period 3: AUC(0-tau) After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval (Urine)
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin
Time frame: Pre-dose, 0-2, 2-4 and 4-6 hours post-dose
Part 1- Period 2: AUC(0-24) After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval (Urine)
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin.
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-12, 12-14, 14-16, 16-18, 18-20 and 20-24 hours post dose
Part 1- Period 3: AUC(0-24) After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval (Urine)
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin.
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-18 and 18-24 hours post-dose
Part 1- Period 2: AUC(0-48) After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval (Urine)
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-12, 12-14, 14-16, 16-18, 18-20, 20-24, 24-36 and 36-48 hours post-dose
Part 1- Period 3: AUC(0-48) After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval (Urine)
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-18, 18-24, 24-36 and 36-48 hours post-dose
Part 1- Period 2: fe% After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. fe% was calculated as: (Ae total/Dose) x 100%.
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-12, 12-14, 14-16, 16-18, 18-20, 20-24, 24-36, 36-48 and 48-60 hours post-dose
Part 1- Period 3: fe% After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. fe% was calculated as: (Ae total/Dose) x 100%.
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-18, 18-24, 24-36, 36-48 and 48-60 hours post-dose
Part 1- Period 2: CLr After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t)
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-12, 12-14, 14-16, 16-18, 18-20, 20-24, 24-36, 36-48 and 48-60 hours post-dose
Part 1- Period 3: CLr After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t)
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-18, 18-24, 24-36, 36-48 and 48-60 hours post-dose
Part 2- Period 1: Ae Total After Single Dose Administration of Gepotidacin 1500 mg
Urine samples were collected at indicated time points. Ae total was calculated by adding all the fractions of drug collected over all the allotted time intervals
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-36 and 36-48 hours post-dose
Part 2- Period 1: Ae(t1-t2) After Single Dose Administration of Gepotidacin 1500 mg
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
Time frame: 0-2, 2-4, 4-6, 6-8, 8-12, 12-24,24-36 and 36-48 hours post-dose
Part 2- Period 1: AUC(0-24) After Single Dose Administration of Gepotidacin 1500 mg (Urine)
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin.
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-12 and 12-24 hours post-dose.
Part 2- Period 1: AUC(0-48) After Single Dose Administration of Gepotidacin 1500 mg (Urine)
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin.
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-36 and 36-48 hours post-dose
Part 2- Period 1: fe% After Single Dose Administration of Gepotidacin 1500 mg
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. fe% was calculated as: (Ae total/Dose) x 100%.
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-36 and 36-48 hours post-dose
Part 2- Period 1: CLr After Single Dose Administration of Gepotidacin 1500 mg
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t).
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-36 and 36-48 hours post-dose
Part 2- Period 2: Ae Total After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval
Urine samples were collected at indicated time points. Ae total was calculated by adding all the fractions of drug collected over all the allotted time intervals.
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-18, 18-24, 24-36 and 36-48 hours post-dose
Part 2- Period 2: Ae(t1-t2) After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
Time frame: 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-18, 18-24, 24-36 and 36-48 hours post-dose
Part 2- Period 2: AUC(0-tau) (Tau=6 Hours Post-dose) After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval (Urine)
Urine samples will be collected at indicated time points for pharmacokinetic analysis of gepotidacin
Time frame: Pre-dose, 0-2, 2-4, 4-6 hours post-dose
Part 2- Period 2: AUC(0-24) After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval (Urine)
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin.
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-18 and 18-24 hours post-dose
Part 2- Period 2: AUC(0-48) After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval (Urine)
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-18, 18-24, 24-36 and 36-48 hours post-dose.
Part 2- Period 2: fe% After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. fe% was calculated as: (Ae total/Dose) x 100%.
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-18, 18-24, 24-36 and 36-48 hours post-dose
Part 2- Period 2: CLr After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t).
Time frame: Pre-dose, 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-18, 18-24, 24-36 and 36-48 hours post-dose
Part 1- Period 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) After Single Dose Administration of Gepotidacin 1500 mg
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Part 1- Period 1: Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) After Single Dose Administration of Gepotidacin 1500 mg
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Part 1- Period 1: Terminal Phase Half-life (t1/2) After Single Dose Administration of Gepotidacin 1500 mg
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Part 1- Period 2: Tmax After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, 24, 36, 48 and 60 hours post-dose
Part 1- Period 3: Tmax After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18, 24, 36, 48 and 60 hours post-dose
Part 1- Period 2: Tlag After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, 24, 36, 48 and 60 hours post-dose
Part 1- Period 3: Tlag After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18, 24, 36, 48 and 60 hours post-dose
Part 1- Period 2: t1/2 After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, 24, 36, 48 and 60 hours post-dose
Part 1- Period 3: t1/2 After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18, 24, 36, 48 and 60 hours post-dose
Part 2- Period 1: Tmax After Single Dose Administration of Gepotidacin 1500 mg
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Part 2- Period 1: Tlag After Single Dose Administration of Gepotidacin 1500 mg
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Part 2- Period 1: t1/2 After Single Dose Administration of Gepotidacin 1500 mg
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Part 2- Period 2: Tmax After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18, 24, 36 and 48 hours post-dose
Part 2- Period 2: Tlag After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18, 24, 36 and 48 hours post-dose
Part 2- Period 2: t1/2 After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 12, 14, 18, 24, 36 and 48 hours post-dose
This was a two-part, double-blind, randomized, sequential study to evaluate pharmacokinetics of Gepotidacin in healthy adult and adolescent participants. The study was conducted at a single center in the United States.
| Milestone | Gepotidacin (A/C/E) | Placebo (B/D/F) | Gepotidacin (A/G) | Placebo (B/H) |
|---|---|---|---|---|
| Started | 14 | 2 | 0 | 0 |
| Completed | 13 | 2 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Milestone | Gepotidacin (A/C/E) | Placebo (B/D/F) | Gepotidacin (A/G) | Placebo (B/H) |
|---|---|---|---|---|
| Started | 13 | 2 | 0 | 0 |
| Completed | 13 | 2 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Gepotidacin (A/C/E) | Placebo (B/D/F) | Gepotidacin (A/G) | Placebo (B/H) |
|---|---|---|---|---|
| Started | 13 | 2 | 0 | 0 |
| Completed | 13 | 2 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Gepotidacin (A/C/E) | Placebo (B/D/F) | Gepotidacin (A/G) | Placebo (B/H) |
|---|---|---|---|---|
| Started | 0 | 0 | 15 | 3 |
| Completed | 0 | 0 | 12 | 3 |
| Not completed | 0 | 0 | 3 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Withdrew: Unable to swallow | 0 | 0 | 2 | 0 |
| Milestone | Gepotidacin (A/C/E) | Placebo (B/D/F) | Gepotidacin (A/G) | Placebo (B/H) |
|---|---|---|---|---|
| Started | 0 | 0 | 12 | 3 |
| Completed | 0 | 0 | 12 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 1500 mg |
|---|---|
| Part 1- Period 1: Area Under the Concentration-time Curve From Time 0 (Pre-dose) to Time of the Last Quantifiable Concentration (AUC[0-t]) After Single Dose Administration of Gepotidacin 1500 mg | 19.69 ± 17.6 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 1500 mg |
|---|---|
| Part 1- Period 1: Area Under the Concentration-time Curve From Time 0 (Pre-dose) Extrapolated to Infinite Time (AUC[0-infinity]) After Single Dose Administration of Gepotidacin 1500 mg | 20.15 ± 16.8 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 1500 mg |
|---|---|
| Part 1- Period 1: Area Under the Concentration-time Curve From Time 0 (Pre-dose) to 24 Hours Post-dose (AUC[0-24]) After Single Dose Administration of Gepotidacin 1500 mg | 18.66 ± 19.5 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 1500 mg |
|---|---|
| Part 1- Period 1: Area Under the Concentration-time Curve From Time 0 (Pre-dose) to 48 Hours Post-dose (AUC[0-48]) After Single Dose Administration of Gepotidacin 1500 mg | 19.72 ± 17.6 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Micrograms per milliliter | Part 1: Gepotidacin 1500 mg |
|---|---|
| Part 1- Period 1: Maximum Observed Concentration (Cmax) After Single Dose Administration of Gepotidacin 1500 mg | 3.574 ± 38.1 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Part 1- Period 2: AUC(0-t) Following Two Doses of Gepotidacin 3000 mg Administered at 12 Hour Dosing Interval | 91.21 ± 22.6 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 1- Period 3: AUC(0-t) Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Dosing Interval | 87.09 ± 26.3 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Dose 1 | 38.15 ± 24.3 |
| Dose 2 | 44.41 ± 22.8 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin.PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Dose 1 | 24.09 ± 33.6 |
| Dose 2 | 40.13 ± 29.5 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Part 1- Period 2: AUC(0-24) Following Two Doses of Gepotidacin 3000 mg Administered at 12 Hour Dosing Interval | 83.45 ± 22.7 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 1- Period 3: AUC(0-24) Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Dosing Interval | 82.43 ± 27.3 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Part 1- Period 2: AUC(0-48) Following Two Doses of Gepotidacin 3000 mg Administered at 12 Hour Dosing Interval | 90.53 ± 22.7 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 1- Period 3: AUC(0-48) Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Dosing Interval | 86.49 ± 26.4 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio was calculated as Cmax after the second dose divided by Cmax after the first dose.
| Ratio | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Part 1- Period 2: Accumulation Ratio for Cmax (RoCmax) Following Two Doses of Gepotidacin 3000 mg Administered at 12 Hour Dosing Interval | 1.109 ± 30.6 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio was calculated as AUC(0-tau) after the second dose, where 0 is the timepoint prior to second dose, divided by AUC(0-tau) after the first dose, where 0 is the predose timepoint prior to the first dose.
| Ratio | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Part 1- Period 2: Accumulation Ratio for AUC (RoAUC) Following Two Doses of Gepotidacin 3000 mg Administered at 12 Hour Dosing Interval | 1.164 ± 12.7 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio was calculated as Cmax after the second dose divided by Cmax after the first dose.
| Ratio | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 1- Period 3: RoCmax Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Dosing Interval | 1.544 ± 25.9 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio was calculated as AUC(0-tau) after the second dose, where 0 is the timepoint prior to second dose, divided by AUC(0-tau) after the first dose, where 0 is the predose timepoint prior to the first dose.
| Ratio | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 1- Period 3: RoAUC Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Dosing Interval | 1.666 ± 25.9 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Micrograms per milliliter | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Dose 1 | 9.937 ± 24.2 |
| Dose 2 | 11.02 ± 28.1 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Micrograms per milliliter | Part1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Dose 1 | 8.423 ± 41.8 |
| Dose 2 | 13.01 ± 28.6 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 2: Gepotidacin 1500 mg |
|---|---|
| Part 2- Period 1: AUC(0-t) After Single Dose Administration of Gepotidacin 1500 mg | 23.27 ± 21.6 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 2: Gepotidacin 1500 mg |
|---|---|
| Part 2- Period 1: AUC(0-infinity) After Single Dose Administration of Gepotidacin 1500 mg | 23.79 ± 20.9 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 2: Gepotidacin 1500 mg |
|---|---|
| Part 2- Period 1: AUC(0-24) After Single Dose Administration of Gepotidacin 1500 mg | 22.06 ± 22.6 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 2: Gepotidacin 1500 mg |
|---|---|
| Part 2- Period 1: AUC(0-48) After Single Dose Administration of Gepotidacin 1500 mg | 23.27 ± 21.6 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Micrograms per milliliter | Part 2: Gepotidacin 1500 mg |
|---|---|
| Part 2- Period 1: Cmax After Single Dose Administration of Gepotidacin 1500 mg | 4.523 ± 29.5 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 2-Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 2- Period 2: AUC(0-t) Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Interval | 115.6 ± 23.8 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Dose 1 | 32.37 ± 22.0 |
| Dose 2 | 53.85 ± 26.7 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis
| Hours*micrograms per milliliter | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 2- Period 2: AUC(0-24) Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Interval | 111.4 ± 23.8 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis
| Hours*micrograms per milliliter | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 2- Period 2: AUC(0-48) Following Two Doses of Gepotidacin 3000 mg Administered at 6 Hour Interval | 115.6 ± 23.8 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were analyzed using standard non-compartmental analysis.
| Micrograms per milliliter | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Dose 1 | 10.86 ± 26.8 |
| Dose 2 | 14.29 ± 29.5 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Number of participants with common (\>=5%) non-serious AEs and SAEs is presented.
| Participants | Part 1: Placebo | Part 1: Gepotidacin 1500 mg | Part 1: Gepotidacin 3000 mg 12 Hour Interval | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|---|---|---|
| Common non-serious AEs | 0 | 1 | 10 | 9 |
| SAEs | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Number of participants with common (\>=5%) non-serious AEs and SAEs are presented.
| Participants | Part 2: Placebo | Part 2: Gepotidacin 1500 mg | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|---|---|
| Common non-serious AEs | 2 | 9 | 12 |
| SAEs | 0 | 0 | 0 |
Blood samples were collected for the analysis of following hematology parameters: platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), white blood cell (WBC) count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. The hematology abnormalities were graded using the Division of Microbiology and Infectious Diseases toxicity grading where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe and Grade 4=Life-threatening. Number of participants with a grade 3 or higher toxicity for any of the hematology parameter is presented.
| Participants | Part 1: Placebo | Part 1: Gepotidacin 1500 mg | Part 1: Gepotidacin 3000 mg 12 Hour Interval | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|---|---|---|
| Part 1: Number of Participants With Hematology Toxicities of Grade 3 or Higher | 0 | 0 | 0 | 0 |
Blood samples were collected for the analysis of following hematology parameters: platelet count, RBC count, hemoglobin, hematocrit, MCV, MCH, WBC count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. The hematology abnormalities were graded using the Division of Microbiology and Infectious Diseases toxicity grading where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe and Grade 4=Life-threatening. Number of participants with a grade 3 or higher toxicity for any of the hematology parameter is presented.
| Participants | Part 2: Placebo | Part 2: Gepotidacin 1500 mg | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|---|---|
| Part 2: Number of Participants With Hematology Toxicities of Grade 3 or Higher | 0 | 0 | 0 |
Blood samples were collected for the analysis of following clinical chemistry parameters: blood urea nitrogen (BUN), creatinine, glucose (fasting), potassium, sodium, magnesium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, total and direct bilirubin, creatine phosphokinase, calcium, chloride, carbon dioxide, total protein and albumin. The clinical chemistry abnormalities were graded using the Division of Microbiology and Infectious Diseases toxicity grading where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe and Grade 4=Life-threatening. Number of participants with a grade 3 or higher toxicity for any of the clinical chemistry parameter is presented
| Participants | Part 1: Placebo | Part 1: Gepotidacin 1500 mg | Part 1: Gepotidacin 3000 mg 12 Hour Interval | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|---|---|---|
| Part 1: Number of Participants With Clinical Chemistry Toxicities of Grade 3 or Higher | 0 | 0 | 0 | 0 |
Blood samples were collected for the analysis of following clinical chemistry parameters: BUN, creatinine, glucose (fasting), potassium, sodium, magnesium, AST, ALT, alkaline phosphatase, total and direct bilirubin, creatine phosphokinase, calcium, chloride, carbon dioxide, total protein and albumin. The clinical chemistry abnormalities were graded using the Division of Microbiology and Infectious Diseases toxicity grading where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe and Grade 4=Life-threatening. Number of participants with a grade 3 or higher toxicity for any of the clinical chemistry parameter is presented
| Participants | Part 2: Placebo | Part 2: Gepotidacin 1500 mg | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|---|---|
| Part 2: Number of Participants With Clinical Chemistry Toxicities of Grade 3 or Higher | 1 | 1 | 3 |
Urine samples were collected for the analysis of urine parameters including specific gravity, potential of hydrogen (pH), glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase. Toxicities were graded using the Division of Microbiology and Infectious Diseases toxicity grading where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe and Grade 4=Life-threatening. Number of participants with a grade 3 or higher toxicity for any of the urine parameter is presented
| Participants | Part 1: Placebo | Part 1: Gepotidacin 1500 mg | Part 1: Gepotidacin 3000 mg 12 Hour Interval | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|---|---|---|
| Part 1: Number of Participants With Urinalysis Toxicities of Grade 3 or Higher | 0 | 0 | 0 | 0 |
Urine samples were collected for the analysis of urine parameters including specific gravity, pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase. Toxicities were graded using the Division of Microbiology and Infectious Diseases toxicity grading where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe and Grade 4=Life-threatening. Number of participants with a grade 3 or higher toxicity for any of the urine parameter is presented
| Participants | Part 2: Placebo | Part 2: Gepotidacin 1500 mg | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|---|---|
| Part 2: Number of Participants With Urinalysis Toxicities of Grade 3 or Higher | 0 | 0 | 0 |
SBP and DBP were measured in a semi-supine position after 5 minutes of rest. The potential clinically important range for vital signs were: SBP (lower: \<85 and upper: \>160 millimeters of mercury \[mmHg\]) and DBP (lower: \<45 and upper: \>100 mmHg).
| Participants | Part 1: Placebo | Part 1: Gepotidacin 1500 mg | Part 1: Gepotidacin 3000 mg 12 Hour Interval | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|---|---|---|
| Part 1: Number of Participants With Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) of Potential Clinical Importance | 0 | 0 | 1 | 1 |
SBP and DBP were measured in a semi-supine position after 5 minutes of rest. The potential clinically important range for vital signs were: SBP (lower: \<85 and upper: \>160 mmHg) and DBP (lower: \<45 and upper: \>100 mmHg).
| Participants | Part 2: Placebo | Part 2: Gepotidacin 1500 mg | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|---|---|
| Part 2: Number of Participants With SBP and DBP of Potential Clinical Importance | 0 | 0 | 0 |
Heart rate was measured in a semi-supine position after 5 minutes of rest. The potential clinically important range for heart rate was (lower:\<40 and upper: \>110 beats per minute).
| Participants | Part 1: Placebo | Part 1: Gepotidacin 1500 mg | Part 1: Gepotidacin 3000 mg 12 Hour Interval | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|---|---|---|
| Part 1: Number of Participants With Abnormal Heart Rate of Potential Clinical Importance | 0 | 0 | 0 | 1 |
Heart rate was measured in a semi-supine position after 5 minutes of rest. The potential clinically important range for heart rate was (lower:\<40 and upper: \>110 beats per minute).
| Participants | Part 2: Placebo | Part 2: Gepotidacin 1500 mg | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|---|---|
| Part 2: Number of Participants With Abnormal Heart Rate of Potential Clinical Importance | 0 | 1 | 0 |
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and corrected QT (QTc) intervals and calculated heart rate. Data for abnormal not clinically significant (NCS) and clinically significant (CS) ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
| Participants | Part 1: Placebo | Part 1: Gepotidacin 1500 mg |
|---|---|---|
| Abnormal, NCS, Day 1- predose, n= 2, 14 | 1 | 8 |
| Abnormal, CS, Day 1- predose, n= 2, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- predose 2, n= 2, 14 | 1 | 11 |
| Abnormal, CS, Day 1-predose 2, n= 2, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- predose 3, n= 2, 14 | 1 | 12 |
| Abnormal, CS, Day 1- predose 3, n= 2, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- 0.5 hours, n= 2, 14 | 0 | 7 |
| Abnormal, CS, Day 1- 0.5 hours, n= 2, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- 1 hour, n= 2, 14 | 0 | 7 |
| Abnormal, CS, Day 1- 1 hour, n= 2, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- 1.5 hours, n= 2, 14 | 0 | 9 |
| Abnormal, CS, Day 1- 1.5 hours, n= 2, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- 2 hours, n= 2, 14 | 0 | 9 |
| Abnormal, CS, Day 1- 2 hours, n= 2, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- 2.5 hours, n= 2, 14 | 1 | 10 |
| Abnormal, CS, Day 1- 2.5 hours, n= 2, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- 3 hours, n= 2, 14 | 0 | 8 |
| Abnormal, CS, Day 1- 3 hours, n= 2, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- 4 hours, n= 2, 14 | 1 | 11 |
| Abnormal, CS, Day 1- 4 hours, n= 2, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- 6 hours, n= 2, 14 | 1 | 9 |
| Abnormal, CS, Day 1- 6 hours, n= 2, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- 8 hours, n= 2, 14 | 1 | 9 |
| Abnormal, CS, Day 1- 8 hours, n= 2, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- 12 hours, n= 2, 14 | 0 | 9 |
| Abnormal, CS, Day 1- 12 hours, n= 2, 14 | 0 | 0 |
| Abnormal, NCS, Day 2- 24 hours, n= 2, 14 | 1 | 10 |
| Abnormal, CS, Day 2- 24 hours, n= 2, 14 | 0 | 0 |
| Abnormal, NCS, Day 2- 36 hours, n= 2, 13 | 0 | 5 |
| Abnormal, CS, Day 2- 36 hours, n= 2, 13 | 0 | 0 |
| Abnormal, NCS, Day 3- 48 hours, n= 2, 13 | 1 | 11 |
| Abnormal, CS, Day 3- 48 hours, n= 2, 13 | 0 | 0 |
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and QTc intervals and calculated heart rate. Data for abnormal NCS and CS ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
| Participants | Part 1: Placebo | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|---|
| Abnormal, NCS, Day 1- predose | 2 | 8 |
| Abnormal, CS, Day 1- predose | 0 | 0 |
| Abnormal, NCS, Day 1- predose 2 | 2 | 8 |
| Abnormal, CS, Day 1-predose 2 | 0 | 0 |
| Abnormal, NCS, Day 1- predose 3 | 1 | 9 |
| Abnormal, CS, Day 1- predose 3 | 0 | 0 |
| Abnormal, NCS, Day 1- 0.5 hours | 1 | 9 |
| Abnormal, CS, Day 1- 0.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 1 hour | 1 | 10 |
| Abnormal, CS, Day 1- 1 hour | 0 | 0 |
| Abnormal, NCS, Day 1- 1.5 hours | 1 | 8 |
| Abnormal, CS, Day 1- 1.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 2 hours | 1 | 9 |
| Abnormal, CS, Day 1- 2 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 2.5 hours | 1 | 7 |
| Abnormal, CS, Day 1- 2.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 3 hours | 1 | 9 |
| Abnormal, CS, Day 1- 3 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 4 hours | 2 | 7 |
| Abnormal, CS, Day 1- 4 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 6 hours | 1 | 9 |
| Abnormal, CS, Day 1- 6 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 8 hours | 1 | 9 |
| Abnormal, CS, Day 1- 8 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 12 hours | 1 | 8 |
| Abnormal, CS, Day 1- 12 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 12.5 hours | 1 | 5 |
| Abnormal, CS, Day 1- 12.5 hours | 0 | 1 |
| Abnormal, NCS, Day 1- 13 hours | 1 | 8 |
| Abnormal, CS, Day 1- 13 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 13.5 hours | 2 | 10 |
| Abnormal, CS, Day 1- 13.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 14 hours | 2 | 7 |
| Abnormal, CS, Day 1- 14 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 14.5 hours | 2 | 9 |
| Abnormal, CS, Day 1- 14.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 15 hours | 1 | 8 |
| Abnormal, CS, Day 1- 15 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 16 hours | 1 | 9 |
| Abnormal, CS, Day 1- 16 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 18 hours | 1 | 11 |
| Abnormal, CS, Day 1- 18 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 20 hours | 1 | 10 |
| Abnormal, CS, Day 1- 20 hours | 0 | 0 |
| Abnormal, NCS, Day 2- 24 hours | 1 | 9 |
| Abnormal, CS, Day 2- 24 hours | 0 | 0 |
| Abnormal, NCS, Day 2- 36 hours | 1 | 8 |
| Abnormal, CS, Day 2- 36 hours | 0 | 0 |
| Abnormal, NCS, Day 3- 48 hours | 1 | 11 |
| Abnormal, CS, Day 3- 48 hours | 0 | 0 |
| Abnormal, NCS, Day 3- 60 hours | 1 | 5 |
| Abnormal, CS, Day 3- 60 hours | 0 | 0 |
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and QTc intervals and calculated heart rate. Data for abnormal NCS and CS ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
| Participants | Part 1: Placebo | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|---|
| Abnormal, NCS, Day 1- predose | 1 | 11 |
| Abnormal, CS, Day 1- predose | 0 | 0 |
| Abnormal, NCS, Day 1- predose 2 | 0 | 9 |
| Abnormal, CS, Day 1-predose 2 | 0 | 0 |
| Abnormal, NCS, Day 1- predose 3 | 1 | 10 |
| Abnormal, CS, Day 1- predose 3 | 0 | 0 |
| Abnormal, NCS, Day 1- 0.5 hours | 1 | 9 |
| Abnormal, CS, Day 1- 0.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 1 hour | 1 | 9 |
| Abnormal, CS, Day 1- 1 hour | 0 | 0 |
| Abnormal, NCS, Day 1- 1.5 hours | 1 | 9 |
| Abnormal, CS, Day 1- 1.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 2 hours | 1 | 9 |
| Abnormal, CS, Day 1- 2 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 2.5 hours | 0 | 8 |
| Abnormal, CS, Day 1- 2.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 3 hours | 1 | 9 |
| Abnormal, CS, Day 1- 3 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 4 hours | 2 | 8 |
| Abnormal, CS, Day 1- 4 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 6 hours | 2 | 7 |
| Abnormal, CS, Day 1- 6 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 6.5 hours | 0 | 7 |
| Abnormal, CS, Day 1- 6.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 7 hours | 0 | 7 |
| Abnormal, CS, Day 1- 7 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 7.5 hours | 0 | 10 |
| Abnormal, CS, Day 1- 7.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 8 hours | 1 | 11 |
| Abnormal, CS, Day 1- 8 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 8.5 hours | 2 | 10 |
| Abnormal, CS, Day 1- 8.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 9 hours | 1 | 11 |
| Abnormal, CS, Day 1- 9 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 10 hours | 2 | 8 |
| Abnormal, CS, Day 1- 10 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 12 hours | 1 | 6 |
| Abnormal, CS, Day 1- 12 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 14 hours | 0 | 7 |
| Abnormal, CS, Day 1- 14 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 18 hours | 1 | 10 |
| Abnormal, CS, Day 1- 18 hours | 0 | 0 |
| Abnormal, NCS, Day 2- 24 hours | 1 | 8 |
| Abnormal, CS, Day 2- 24 hours | 0 | 0 |
| Abnormal, NCS, Day 2- 36 hours | 0 | 10 |
| Abnormal, CS, Day 2- 36 hours | 0 | 0 |
| Abnormal, NCS, Day 3- 48 hours | 1 | 10 |
| Abnormal, CS, Day 3- 48 hours | 0 | 0 |
| Abnormal, NCS, Day 3- 60 hours | 0 | 8 |
| Abnormal, CS, Day 3- 60 hours | 0 | 0 |
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and QTc intervals and calculated heart rate. Data for abnormal NCS and CS were presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
| Participants | Part 2: Placebo | Part 2: Gepotidacin 1500 mg |
|---|---|---|
| Abnormal, NCS, Day 1- predose, n= 3, 14 | 1 | 4 |
| Abnormal, CS, Day 1- predose, n= 3, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- predose 2, n= 3, 14 | 0 | 5 |
| Abnormal, CS, Day 1-predose 2, n= 3, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- predose 3, n= 3, 14 | 0 | 4 |
| Abnormal, CS, Day 1- predose 3, n= 3, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- 0.5 hours, n= 3, 14 | 0 | 5 |
| Abnormal, CS, Day 1- 0.5 hours, n= 3, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- 1 hour, n= 3, 13 | 0 | 7 |
| Abnormal, CS, Day 1- 1 hour, n= 3, 13 | 0 | 0 |
| Abnormal, NCS, Day 1- 1.5 hours, n= 3, 13 | 0 | 4 |
| Abnormal, CS, Day 1- 1.5 hours, n= 3, 13 | 0 | 0 |
| Abnormal, NCS, Day 1- 2 hours, n= 3, 13 | 0 | 4 |
| Abnormal, CS, Day 1- 2 hours, n= 3, 13 | 0 | 0 |
| Abnormal, NCS, Day 1- 2.5 hours, n= 3, 13 | 0 | 4 |
| Abnormal, CS, Day 1- 2.5 hours, n= 3, 13 | 0 | 0 |
| Abnormal, NCS, Day 1- 3 hours, n= 3, 13 | 1 | 6 |
| Abnormal, CS, Day 1- 3 hours, n= 3, 13 | 0 | 0 |
| Abnormal, NCS, Day 1- 4 hours, n= 3, 14 | 0 | 5 |
| Abnormal, CS, Day 1- 4 hours, n= 3, 14 | 0 | 0 |
| Abnormal, NCS, Day 1- 6 hours, n= 3, 13 | 0 | 6 |
| Abnormal, CS, Day 1- 6 hours, n= 3, 13 | 0 | 0 |
| Abnormal, NCS, Day 1- 8 hours, n= 3, 13 | 1 | 3 |
| Abnormal, CS, Day 1- 8 hours, n= 3, 13 | 0 | 0 |
| Abnormal, NCS, Day 1- 12 hours, n= 3, 13 | 0 | 6 |
| Abnormal, CS, Day 1- 12 hours, n= 3, 13 | 0 | 0 |
| Abnormal, NCS, Day 1- 24 hours, n= 3, 13 | 2 | 4 |
| Abnormal, CS, Day 1- 24 hours, n= 3, 13 | 0 | 0 |
| Abnormal, NCS, Day 1- 36 hours, n= 3, 13 | 0 | 3 |
| Abnormal, CS, Day 1- 36 hours, n= 3, 13 | 0 | 0 |
| Abnormal, NCS, Day 1- 48 hours, n= 3, 13 | 2 | 5 |
| Abnormal, CS, Day 1- 48 hours, n= 3, 13 | 0 | 0 |
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes. Twelve lead ECGs were obtained by using an automated ECG machine that measured PR, QRS, QT, and QTc intervals and calculated heart rate. Data for abnormal NCS and CS were presented CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
| Participants | Part 2: Placebo | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|---|
| Abnormal, NCS, Day 1- predose | 1 | 6 |
| Abnormal, CS, Day 1- predose | 0 | 0 |
| Abnormal, NCS, Day 1- predose 2 | 1 | 7 |
| Abnormal, CS, Day 1-predose 2 | 0 | 0 |
| Abnormal, NCS, Day 1- predose 3 | 1 | 7 |
| Abnormal, CS, Day 1- predose 3 | 0 | 0 |
| Abnormal, NCS, Day 1- 0.5 hours | 1 | 6 |
| Abnormal, CS, Day 1- 0.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 1 hour | 1 | 6 |
| Abnormal, CS, Day 1- 1 hour | 0 | 0 |
| Abnormal, NCS, Day 1- 1.5 hours | 0 | 4 |
| Abnormal, CS, Day 1- 1.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 2 hours | 0 | 6 |
| Abnormal, CS, Day 1- 2 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 2.5 hours | 0 | 5 |
| Abnormal, CS, Day 1- 2.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 3 hours | 0 | 5 |
| Abnormal, CS, Day 1- 3 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 4 hours | 1 | 5 |
| Abnormal, CS, Day 1- 4 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 6 hours | 1 | 3 |
| Abnormal, CS, Day 1- 6 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 6.5 hours | 1 | 5 |
| Abnormal, CS, Day 1- 6.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 7 hours | 1 | 5 |
| Abnormal, CS, Day 1- 7 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 7.5 hours | 0 | 3 |
| Abnormal, CS, Day 1- 7.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 8 hours | 0 | 3 |
| Abnormal, CS, Day 1- 8 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 8.5 hours | 0 | 3 |
| Abnormal, CS, Day 1- 8.5 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 9 hours | 0 | 4 |
| Abnormal, CS, Day 1- 9 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 10 hours | 1 | 5 |
| Abnormal, CS, Day 1- 10 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 12 hours | 0 | 4 |
| Abnormal, CS, Day 1- 12 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 14 hours | 0 | 4 |
| Abnormal, CS, Day 1- 14 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 18 hours | 1 | 7 |
| Abnormal, CS, Day 1- 18 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 24 hours | 1 | 6 |
| Abnormal, CS, Day 1- 24 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 36 hours | 0 | 4 |
| Abnormal, CS, Day 1- 36 hours | 0 | 0 |
| Abnormal, NCS, Day 1- 48 hours | 2 | 7 |
| Abnormal, CS, Day 1- 48 hours | 0 | 0 |
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. Ae total was calculated by adding all the fractions of drug collected over all the allotted time intervals.
| Milligrams | Part 1: Gepotidacin 1500 mg |
|---|---|
| Part 1- Period 1: Total Unchanged Drug (Ae Total) After Single Dose Administration of Gepotidacin 1500 mg | 328.1 ± 68.09 |
Urine samples were collected at the specified intervals for PK analysis. PK parameters were calculated using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
| Milligrams | Part 1: Gepotidacin 1500 mg |
|---|---|
| Ae (0-2), n=14 | 50.87 ± 61.194 |
| Ae (2-4), n=13 | 92.98 ± 51.315 |
| Ae (4-6), n=13 | 68.14 ± 39.927 |
| Ae (6-8), n=14 | 47.68 ± 25.551 |
| Ae (8-12), n=14 | 35.71 ± 11.458 |
| Ae (12-24), n=14 | 29.10 ± 7.8849 |
| Ae (24-36), n=13 | 10.72 ± 4.2330 |
| Ae (36-48), n=13 | 5.601 ± 2.0351 |
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 1500 mg |
|---|---|
| Part 1- Period 1: AUC(0-24) After Single Dose Administration of Gepotidacin 1500 mg (Urine) | 3340.0 ± 2340.34 |
Urine samples were be collected at indicated time points for pharmacokinetic analysis of gepotidacin.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 1500 mg |
|---|---|
| Part 1- Period 1: AUC(0-48) After Single Dose Administration of Gepotidacin 1500 mg (Urine) | 3567.9 ± 2377.71 |
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. fe% was calculated as: (Ae total/Dose) x 100 percent (%).
| Percent dose excreted | Part 1: Gepotidacin 1500 mg |
|---|---|
| Part 1- Period 1: Percentage of the Given Dose of Drug Excreted in Urine (fe%) After Single Dose Administration of Gepotidacin 1500 mg | 21.874 ± 4.5393 |
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t)
| Liters per hour | Part 1: Gepotidacin 1500 mg |
|---|---|
| Part 1- Period 1: Renal Clearance of Drug (CLr) After Single Dose Administration of Gepotidacin 1500 mg | 16.66 ± 3.4123 |
Urine samples were collected at indicated time points. Ae total were calculated by adding all the fractions of drug collected over all the allotted time intervals.
| Milligrams | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Part 1- Period 2: Ae Total After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval | 1452.7 ± 223.10 |
Urine samples were collected at indicated time points. Ae total were calculated by adding all the fractions of drug collected over all the allotted time intervals
| Milligrams | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 1- Period 3: Ae Total After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval | 1293.9 ± 367.48 |
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals
| Milligrams | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Ae (0-2), n=13 | 158.5 ± 81.599 |
| Ae (2-4), n=12 | 186.1 ± 73.777 |
| Ae (4-6), n=13 | 143.6 ± 73.790 |
| Ae (6-8), n=12 | 66.80 ± 22.886 |
| Ae (8-12), n=13 | 64.98 ± 23.987 |
| Ae (12-14), n=12 | 204.1 ± 113.98 |
| Ae (14-16), n=13 | 254.3 ± 83.985 |
| Ae (16-18), n=12 | 156.7 ± 85.023 |
| Ae (18-20), n=13 | 80.29 ± 43.563 |
| Ae (20-24), n=13 | 79.23 ± 25.216 |
| Ae (24-36), n=13 | 74.53 ± 21.862 |
| Ae (36-48), n=13 | 20.35 ± 5.7977 |
| Ae (48-60), n=13 | 10.51 ± 5.0038 |
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
| Milligrams | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Ae (0-2), n=12 | 97.51 ± 70.551 |
| Ae (2-4), n=10 | 216.8 ± 97.543 |
| Ae (4-6), n=13 | 172.2 ± 98.842 |
| Ae (6-8), n=12 | 242.3 ± 138.61 |
| Ae (8-10), n=11 | 251.0 ± 115.23 |
| Ae (10-12), n=12 | 151.6 ± 91.694 |
| Ae (12-14), n=12 | 107.3 ± 77.898 |
| Ae (14-18), n=12 | 72.83 ± 27.363 |
| Ae (18-24), n=12 | 63.91 ± 48.404 |
| Ae (24-36), n=13 | 39.13 ± 12.057 |
| Ae (36-48), n=13 | 15.64 ± 5.9580 |
| Ae (48-60), n=13 | 8.889 ± 4.1747 |
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Part 1- Period 2: AUC(0-tau) (Tau=12 Hours Post-dose) After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval (Urine) | 7287.4 ± 4050.81 |
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin
| Hours*micrograms per milliliter | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 1- Period 3: AUC(0-tau) After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval (Urine) | 3943.5 ± 3015.98 |
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Part 1- Period 2: AUC(0-24) After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval (Urine) | 17431.6 ± 10132.84 |
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin.
| Hours*micrograms per milliliter | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 1- Period 3: AUC(0-24) After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval (Urine) | 13174.1 ± 8648.92 |
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin
| Hours*micrograms per milliliter | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Part 1- Period 2: AUC(0-48) After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval (Urine) | 19128.3 ± 10934.06 |
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin
| Hours*micrograms per milliliter | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 1- Period 3: AUC(0-48) After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval (Urine) | 14277.1 ± 9045.37 |
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. fe% was calculated as: (Ae total/Dose) x 100%.
| Percent dose excreted | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Part 1- Period 2: fe% After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval | 24.212 ± 3.7184 |
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. fe% was calculated as: (Ae total/Dose) x 100%.
| Percent dose excreted | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 1- Period 3: fe% After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval | 21.565 ± 6.1246 |
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t)
| Liters per hour | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Part 1- Period 2: CLr After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval | 15.88 ± 2.0305 |
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t)
| Liters per hour | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 1- Period 3: CLr After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval | 14.81 ± 3.4456 |
Urine samples were collected at indicated time points. Ae total was calculated by adding all the fractions of drug collected over all the allotted time intervals
| Milligrams | Part 2: Gepotidacin 1500 mg |
|---|---|
| Part 2- Period 1: Ae Total After Single Dose Administration of Gepotidacin 1500 mg | 361.5 ± 83.95 |
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
| Milligrams | Part 2: Gepotidacin 1500 mg |
|---|---|
| Ae (0-2), n=13 | 16.00 ± 28.532 |
| Ae (2-4), n=12 | 130.5 ± 49.526 |
| Ae (4-6), n=12 | 85.47 ± 37.814 |
| Ae (6-8), n=13 | 58.74 ± 32.586 |
| Ae (8-12), n=13 | 40.15 ± 14.232 |
| Ae (12-24), n=13 | 30.87 ± 11.638 |
| Ae (24-36), n=13 | 10.11 ± 4.6348 |
| Ae (36-48), n=13 | 6.312 ± 2.5619 |
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin.
| Hours*micrograms per milliliter | Part 2: Gepotidacin 1500 mg |
|---|---|
| Part 2- Period 1: AUC(0-24) After Single Dose Administration of Gepotidacin 1500 mg (Urine) | 4513.7 ± 2623.81 |
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin.
| Hours*micrograms per milliliter | Part 2: Gepotidacin 1500 mg |
|---|---|
| Part 2- Period 1: AUC(0-48) After Single Dose Administration of Gepotidacin 1500 mg (Urine) | 4948.4 ± 2721.49 |
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. fe% was calculated as: (Ae total/Dose) x 100%.
| Percent dose excreted | Part 2: Gepotidacin 1500 mg |
|---|---|
| Part 2- Period 1: fe% After Single Dose Administration of Gepotidacin 1500 mg | 24.100 ± 5.5968 |
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t).
| Liters per hour | Part 2: Gepotidacin 1500 mg |
|---|---|
| Part 2- Period 1: CLr After Single Dose Administration of Gepotidacin 1500 mg | 15.56 ± 3.7934 |
Urine samples were collected at indicated time points. Ae total was calculated by adding all the fractions of drug collected over all the allotted time intervals.
| Milligrams | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 2- Period 2: Ae Total After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval | 1719.4 ± 402.71 |
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
| Milligrams | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Ae (0-2), n=11 | 105.3 ± 121.67 |
| Ae (2-4), n=10 | 202.0 ± 70.108 |
| Ae (4-6), n=10 | 229.7 ± 113.95 |
| Ae (6-8), n=11 | 244.9 ± 149.66 |
| Ae (8-10), n=12 | 446.6 ± 138.33 |
| Ae (10-12), n=10 | 228.3 ± 79.619 |
| Ae (12-14), n=11 | 172.5 ± 63.150 |
| Ae (14-18), n=10 | 132.6 ± 51.586 |
| Ae (18-24), n=10 | 67.56 ± 40.521 |
| Ae (24-36), n=12 | 61.99 ± 51.367 |
| Ae (36-48), n=12 | 14.86 ± 8.3210 |
Urine samples will be collected at indicated time points for pharmacokinetic analysis of gepotidacin
| Hours*micrograms per milliliter | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 2- Period 2: AUC(0-tau) (Tau=6 Hours Post-dose) After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval (Urine) | 5364.4 ± 2877.94 |
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin.
| Hours*micrograms per milliliter | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 2- Period 2: AUC(0-24) After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval (Urine) | 22052.8 ± 11410.09 |
Urine samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin
| Hours*micrograms per milliliter | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 2- Period 2: AUC(0-48) After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval (Urine) | 24500.7 ± 12281.23 |
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. fe% was calculated as: (Ae total/Dose) x 100%.
| Percent dose excreted | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 2- Period 2: fe% After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval | 28.657 ± 6.7119 |
Urine samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis. CLr was calculated as: Ae total/AUC(0-t).
| Liters per hour | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 2- Period 2: CLr After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval | 14.93 ± 3.9558 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
| Hours | Part 1: Gepotidacin 1500 mg |
|---|---|
| Part 1- Period 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) After Single Dose Administration of Gepotidacin 1500 mg | 3.000 (0.50 to 6.00) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
| Hours | Part 1: Gepotidacin 1500 mg |
|---|---|
| Part 1- Period 1: Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) After Single Dose Administration of Gepotidacin 1500 mg | 0.000 (0.00 to 1.50) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
| Hours | Part 1: Gepotidacin 1500 mg |
|---|---|
| Part 1- Period 1: Terminal Phase Half-life (t1/2) After Single Dose Administration of Gepotidacin 1500 mg | 11.533 ± 36.2 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
| Hours | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Dose 1 | 2.000 (1.00 to 4.00) |
| Dose 2 | 1.567 (1.00 to 4.00) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
| Hours | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Dose 1 | 2.633 (0.50 to 5.42) |
| Dose 2 | 1.500 (1.00 to 3.28) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
| Hours | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Part 1- Period 2: Tlag After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval | 0.000 (0.00 to 0.00) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
| Hours | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 1- Period 3: Tlag After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval | 0.000 (0.00 to 0.00) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
| Hours | Part 1: Gepotidacin 3000 mg 12 Hour Interval |
|---|---|
| Part 1- Period 2: t1/2 After Two Doses Administration of Gepotidacin 3000 mg at 12 Hour Dosing Interval | 10.976 ± 27.3 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
| Hours | Part 1: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 1- Period 3: t1/2 After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Dosing Interval | 12.020 ± 14.6 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
| Hours | Part 2: Gepotidacin 1500 mg |
|---|---|
| Part 2- Period 1: Tmax After Single Dose Administration of Gepotidacin 1500 mg | 3.000 (1.50 to 6.50) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
| Hours | Part 2: Gepotidacin 1500 mg |
|---|---|
| Part 2- Period 1: Tlag After Single Dose Administration of Gepotidacin 1500 mg | 0.500 (0.00 to 1.50) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
| Hours | Part 2: Gepotidacin 1500 mg |
|---|---|
| Part 2- Period 1: t1/2 After Single Dose Administration of Gepotidacin 1500 mg | 12.984 ± 16.6 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
| Hours | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Dose 1 | 2.750 (1.00 to 4.00) |
| Dose 2 | 1.500 (1.00 to 3.00) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
| Hours | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 2- Period 2: Tlag After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval | 0.000 (0.00 to 0.50) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of gepotidacin. PK parameters were calculated using standard non-compartmental analysis.
| Hours | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|
| Part 2- Period 2: t1/2 After Two Doses Administration of Gepotidacin 3000 mg at 6 Hour Interval | 6.982 ± 19.7 |
Collected over Non-SAEs and SAEs were collected from start of study intervention (Day 1) up to Day 19 for Part 1 and up to Day 21 for Part 2.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 : Placebo | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Part1: Gepotidacin 1500 mg | 0/14 (0%) | 0/14 (0%) | 1/14 (7.1%) |
| Part 1: Gepotidacin 3000 mg 12 Hour Interval | 0/13 (0%) | 0/13 (0%) | 10/13 (76.9%) |
| Part 1: Gepotidacin 3000 mg 6 Hour Interval | 0/13 (0%) | 0/13 (0%) | 9/13 (69.2%) |
| Part 2 : Placebo | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Part 2: Gepotidacin 1500 mg | 0/14 (0%) | 0/14 (0%) | 9/14 (64.3%) |
| Part 2: Gepotidacin 3000 mg 6 Hour Interval | 0/12 (0%) | 0/12 (0%) | 12/12 (100%) |
| Event | Part 1 : Placebo | Part1: Gepotidacin 1500 mg | Part 1: Gepotidacin 3000 mg 12 Hour Interval | Part 1: Gepotidacin 3000 mg 6 Hour Interval | Part 2 : Placebo | Part 2: Gepotidacin 1500 mg | Part 2: Gepotidacin 3000 mg 6 Hour Interval |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/2 | 0/14 | 2/13 | 3/13 | 1/3 | 0/14 | 9/12 |
| DiarrhoeaGastrointestinal disorders | 0/2 | 1/14 | 8/13 | 8/13 | 1/3 | 3/14 | 5/12 |
| VomitingGastrointestinal disorders | 0/2 | 0/14 | 1/13 | 2/13 | 0/3 | 0/14 | 5/12 |
| Abdominal discomfortGastrointestinal disorders | 0/2 | 0/14 | 4/13 | 4/13 | 1/3 | 2/14 | 3/12 |
| DizzinessNervous system disorders | 0/2 | 0/14 | 0/13 | 0/13 | 1/3 | 0/14 | 4/12 |
| HeadacheNervous system disorders | 0/2 | 0/14 | 0/13 | 0/13 | 1/3 | 2/14 | 1/12 |
| SyncopeNervous system disorders | 0/2 | 0/14 | 0/13 | 0/13 | 1/3 | 0/14 | 0/12 |
| FlatulenceGastrointestinal disorders | 0/2 | 0/14 | 0/13 | 0/13 | 0/3 | 2/14 | 2/12 |
| Supraventricular extrasystolesCardiac disorders | 0/2 | 0/14 | 0/13 | 0/13 | 0/3 | 0/14 | 1/12 |
| Chest discomfortGeneral disorders | 0/2 | 0/14 | 0/13 | 0/13 | 0/3 | 0/14 | 1/12 |
| Age, Categorical(Participants) | Gepotidacin (A/C/E) | Placebo (B/D/F) | Gepotidacin (A/G) | Placebo (B/H) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 14 | 3 | 17 |
| Between 18 and 65 years | 14 | 2 | 0 | 0 | 16 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Gepotidacin (A/C/E) | Placebo (B/D/F) | Gepotidacin (A/G) | Placebo (B/H) | Total |
|---|---|---|---|---|---|
| Female | 6 | 1 | 4 | 1 | 12 |
| Male | 8 | 1 | 10 | 2 | 21 |
| Race/Ethnicity, Customized(Participants) | Gepotidacin (A/C/E) | Placebo (B/D/F) | Gepotidacin (A/G) | Placebo (B/H) | Total |
|---|---|---|---|---|---|
| Asian- Central/South Asian Heritage | 1 | 0 | 1 | 0 | 2 |
| Black or African American | 6 | 0 | 6 | 1 | 13 |
| White-Arabic/North African Heritage | 1 | 0 | 0 | 0 | 1 |
| White-White/Caucasian/European Heritage | 6 | 2 | 5 | 2 | 15 |
| Multiple | 0 | 0 | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Sep 2019 to primary completion in Nov 2019, 2 months.
Results were first posted in Sep 2020, 9 months after primary completion.
Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 2 months is below that.
Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gepotidacin